Molecular mechanisms of muscle atrophy in myotonic dystrophies

International Journal of Biochemistry and Cell Biology

Volumn 45, Issue 10, 2013, Pages 2280-2287

  Timchenko, Lubov ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

CUG CCUG repeats; Muscle atrophy; Myotonic dystrophy type 1; Myotonic dystrophy type 2; Therapeutic approaches

Indexed keywords

MYOTONIC DYSTROPHY PROTEIN KINASE; RNA BINDING PROTEIN;

HISTOPATHOLOGY; HUMAN; MOLECULAR MECHANICS; MUSCLE ATROPHY; MUSCLE WEAKNESS; MYOTONIC DYSTROPHY; NONHUMAN; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW;

CUG/CCUG REPEATS; MUSCLE ATROPHY; MYOTONIC DYSTROPHY TYPE 1; MYOTONIC DYSTROPHY TYPE 2; THERAPEUTIC APPROACHES;

ANIMALS; HUMANS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MYOTONIC DISORDERS; MYOTONIC DYSTROPHY;

EID: 84885176026     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2013.06.010     Document Type: Review

References (83)

1. Amack JD, Mahadevan MS. Myogenic defects in myotonic dystrophy. Developmental Biology 2004; 265:294-301.
2. Berger DS, Moyer M, Kliment GM, van Lunteren E, Ladd AN. Expression of a dominant negative CELF protein in vivo leads to altered muscle organization, fiber size and subtype. PLoS ONE 2011; 6:e19274.
3. Bigot A, Klein AF, Gasnier E, Jacquemin V., Ravassard P, Butler-Browne G, et al Large CTG repeats trigger p16-dependent premature senescence in myotonic dystrophy type 1 muscle precursor cells. American Journal of Pathology 2009; 174:1435-42.
4. Botta A, Caldarola S, Vallo L., Bonifazi E, Fruci D, Gullotta F, et al. Effect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy II (DM2). Biochimicaet Biophysica Acta 2006; 1762:329-34.
5. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeats at the 3' end of a transcript encoding a protein kinase family member. Cell 1992; 68:799-808.
6. Calcaterra NB, Armas P, Weiner AM, Borgognone M. CNBP: a multifunctional nucleic acid chaperone involved in cell death and proliferation control. IUBMB Life 2010; 62:707-14.
7. Charlet BN, Savcur RS, Singh G, Philips A.V., Grice EA, Cooper TA Loss of the muscle specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Molecular Cell 2002; 10:45-53.
8. Chen W, Wang Y, Abe Y., Cheney L, Udd B, Li YP Haploinsuffciency for ZNF9 in ZNF9+/-mice is associated with multiorgan abnormalities resembling myotonic dystrophy. Journal of Molecular Biology 2007; 368:8-17.
9. Fu YH, Pizzuti A, Fenwick RG Jr, King J, Rajnarayan S, Dunne P.W., et al An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992; 255:1256-8.
10. Fugier C, Klein AF, Hammer C, Vassilopoulos S., Ivarsson Y, Toussaint A, et al Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nature Medicine 2011; 17:720-5.
11. Harper PS. Myotonic dystrophy. London: WB Saunders; 2001.
12. Ho TH, Bundman D, Armstrong DL, Cooper TA. Transgenic mice overexpressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Human Molecular Genetics 2005; 14:1539-47.
13. Huguet A, Medja F, Nicole A., Vignaud A, Guiraud-Dogan C, Ferry A, et al Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus. PLoS Genetics 2012; 8:e1003043.
14. Huichalaf C, Sakai K, Jin B., Jones K, Wang G-L, Schoser B, et al Expansion of CUG RNA repeats causes stress and inhibition of translation in myotonic dystrophy 1 cells. FASEBJournal 2010; 24:3706-19.
15. Huichalaf C, Schoser B, Schneider-Gold C, Jin B., Sarkar P, Timchenko L. Reduction the rate of protein translation in patients with myotonic dystrophy 2. Journal of Neuroscience 2009; 29:9042-9.
16. Jones K, Jin B, Huichalaf C., Sarkar P, Schneider-Gold C, Schoser B, et al RNA foci, CUGBP1 and ZNF9 are primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2. American Journal of Pathology 2011; 179:2475-89.
17. Jones K, Wei C, Iakova P., Bugiardini E, Schneider-Gold C, Meola G, et al GSK3β mediates muscle pathology in myotonic dystrophy. Journal of Clinical Investigation 2012; 122:4461-72.
18. Kalsotra A, Xiao X, Ward A.J., Castle JC, Burge CB, et al A postnatal switch of CELF and MBNL1 proteins reprograms alternative splicing in the developing heart. Proceedings of the National Academy of Sciences of the United States of America 2008; 105:20333-8.
19. Kanadia RN, Johnstone KA, Mankodi A, Lungu C., Thornton CA, Esson D, et al A muscleblind knockout model for myotonic dystrophy. Science 2003; 302:1978-80.
20. Kanadia RN, Shin J, Yuan Y., Beattie SG, Wheeler TM, Thornton CA, et al Reversal of RNA missplicingand myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proceedings of the National Academy of Sciences of the United States of America 2006; 103:11748-55.
21. 2+-ATPase in myotonic dystrophy type 1. Human Molecular Genetics 2005; 14:2189-200.
22. Kuyumcu-Martinez N.M., Wang G-S, Cooper TA Increased steady-state levels of CUGBP1 in myotonic dystrophy are due to PKC-mediatedhyperphosphorylation. Molecular Cell 2007; 28:68-78.
23. Lagirand-Cantaloube J., Offner N, Csibi A., Leibovitch MP, Batonnet-Pichon S, Tintignac LA, et al The initiation factor eIF3-f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophy. EMBO Journal 2008; 27:1266-76.
24. Lee JE, Bennett F, Cooper TA RNAase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proceedings of the National Academy of Sciences of the United States of America 2012; 09:4221-6.
25. Lee JE, Lee JY, Wilusz J, Tian B., Wilusz CJ Systematic analysis of cis-elements in unstable mRNAs demonstrates that CUGBP1 is a key regulator of mRNA decay in muscle cells. PLoS ONE 2010; 5:e11201.
26. Lin X, Miller JW, Mankodi A, Kanadia R.N., Yuan Y., Moxley RT, et al Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Human Molecular Genetics 2006; 15:2087-97.
27. Liquori CL, Ricker K, Moseley M.L., Jacobsen JF, Kress W, Naylor SL, et al Myotonic dystrophy 2 is caused by CCTG expansion in intron 1 of ZNF9. Science 2001; 293:864-7.
28. Mahadevan MS, Yadava RS, Yu Q, Balijepalli S., Frenzel-McCardell CD, Bourne TD, et al Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nature Genetics 2006; 38:1066-70.
29. Mankodi A, Logigian E, Callahan L., McClain C, White R, Henderson D., et al Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 2000; 289:1769-72.
30. Mankodi A, Takahashi MP, Jiang H, Beck C.L., Bowers WJ, Moxley RT, et al Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Molecular Cell 2002; 10:35-44.
31. Mankodi A, Urbinati CR, Yuan Q.P., Moxley RT, Sansone V, Krym M, et al Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Human Molecular Genetics 2001; 10:2165-70.
32. Margolis JM, Schoser BG, Moseley M.L., Day JW, Ranum LP DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. Human Molecular Genetics 2006; 15:1808-15.
33. Masuda A, Andersen HS, Doktor T.K., Okamoto T., Ito M, Andresen BS, et al CUGBP1 and MBNL1 preferentially bind to 3' UTRs and facilitate mRNA decay. Scientific Reports 2012; 2:209.
34. Meyuhas O. Synthesis of the translational apparatus is regulated at the translational level. European Journal of Biochemistry 2000; 267:6321-30.
35. Mientjes EJ, Willemsen R, Kirkpatrick L.L., Nieuwenhuizen IM, Hoogeveen-Westerveld M, Verweij M, et al Fxr1 knockout mice show a striated muscle phenotype: implications for Fxr1p function in vivo. Human Molecular Genetics 2004; 13:1291-302.
36. Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg M.G., Byrne BJ, Thornton CA, et al Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy. EMBO Journal 2000; 19:4439-48.
37. Moraes KC, Wilusz CJ, Wilusz J. CUG-BP binds to RNA substrates and recruits PARN deadenylase. RNA 2006; 12:1084-91.
38. Moyer M, Berger DS, Ladd AN, van Lunteren E. Differential susceptibility of muscles to myotonia and force impairment in a mouse model of myotonic dystrophy. Muscle Nerve 2011; 43:818-27.
39. Mulders SAM, van den Broek WJAA, Wheeler TM, Croes HJE, van Kuik-Romeijn P, de Kimpe SJ, et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proceedings of the National Academy of Sciences of the United States of America 2009; 106:13915-20.
40. Naderi S, Gutzkow KB, Lahne H.U., Lefdal S., Ryves WJ, Harwood AJ, et al cAMP induced degradation of cyclin D3 through association with GSK-3 beta. Journal of Cell Science 2004; 117:3769-83.
41. Orengo J, Chambon P, Metzger D, Mosier DR, Snipes GL, Copper TA. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proceedings of the National Academy of Sciences of the United States of America 2008; 105:2646-51.
42. Osborne RJ, Lin X, Welle S., Sobczak K, O'Rourke JR, Swanson MS, et al Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Human Molecular Genetics 2009; 18:1471-81.
43. Paillard L, Omilli F, Legagneux V., Bassez T, Maniey D, Osborne HB EDEN and EDEN BP, a cis element and an associated factorthat mediate sequence-specific mRNA deadenylation in Xenopus laevis embryos. EMBO Journal 1998; 17:278-87.
44. Pelletier R, Hamel F, Beaulieu D., Patry L, Haineault C, Tarnopolsky M., et al Absence of a differentiation defect in muscle satellite cells from DM2 patients. Neurobiology of Disease 2009; 36:181-90.
45. Pellizzoni L, Lotti F, Maras B., Pierandrei-Amaldi P. Cellular nucleic acid binding protein binds a conserved region of the 5' UTR of Xenopus laevis ribosomal protein mRNAs. Journal of Molecular Biology 1997; 267:264-75.
46. Philips AV, Timchenko LT, Cooper TA Disruption of splicing of regulated by CUG binding protein in myotonic dystrophy. Science 1998; 280:737-41.
47. Raheem O, Olufemi SE, Bachinski L.L., Vihola A., Sirito M, Holmlund-Hampf J, et al Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2. American Journal of Pathology 2010; 177:3025-36.
48. Ranum LP, Cooper TA RNA-mediated neuromuscular disorders. Annual Review of Neuroscience 2006; 29:259-77.
49. Rattenbacher B, Beisang D, Wiesner D.L., Jeschke JC, von Hohenberg M, St Louis-Vlasova IA, et al. Analysis of CUGBP1 targets identifies GU-repeat sequences that mediate rapid mRNA decay. Molecular and Cellular Biology 2010; 30:3970-80.
50. Rau F, Freyermuth F, Fugier C, Villemin J-P, Fischer M-C, Jost B, et al. Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. Nature Structural & Molecular Biology 2011; 18:840-5.
51. Reardon W, Newcombe R, Fenton I., Sibert J, Harper PS The natural history of congenital myotonic dystrophy: mortality and long term clinical aspects. Archives of Disease in Childhood 1993; 68:177-81.
52. Ricker K, Koch MC, Lehmann-Horn F, Pongratz D., Otto M, Heine R, et al Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1995; 44:1448-52.
53. Rusconi F, Mancinelli E, Colombo G., Cardani R, Da Riva L, Bongarzone I, et al Proteome profile in myotonic dystrophy type 2 myotubes reveals dysfunction in protein processing and mitochondrial pathways. Neurobiology of Disease 2010; 38:273-80.
54. Salisbury E, Sakai K, Schoser B., Huichalaf C, Schneider-Gold C, Nguen H, et al Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUGBP1. Experimental Cell Research 2008; 314:2266-78.
55. Salisbury E, Schoser B, Schneider-Gold C, Wang G.L., Huichalaf C., Jin B, et al Expression of RNA CCUG repeats dysregulates translation and degradation of proteins in DM2 patients. American Journal of Pathology 2009; 175:748-62.
56. Sammons MA, Antons AK, Bendjennat M, Udd B., Krahe R, Link AJ. ZNF9 activation of IRES-mediated translation of the human ODC mRNA is decreased in myotonic dystrophy type 2. PLoS ONE 2010; 5:e09301.
57. Sammons MA, Samir P, Link AJ Saccharomyces cerevisiae Gis2 interacts with the translation machinery and is orthogonal to myotonic dystrophy type 2 protein ZNF9. Biochemical and Biophysical Research Communications 2011; 406:13-9.
58. Savkur RS, Philips AV, Cooper TA Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nature Genetics 2001; 29:40-7.
59. Scherrer T, Femmer C, Schiess R., Aebersold R, Gerber AP Defining potentially conserved RNA regulons of homologous zinc-finger RNA-binding proteins. Genome Biology 2011; 12:R3.
60. Schoser B, Timchenko L. Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms. Current Genomics 2010; 11:79-90.
61. Seznec H, Agbulut O, Sergeant N., Savouret C, Ghestem A, Tabti N., et al Mice transgenic for the human dystrophy region with expanded CTG repeats display muscular and brain abnormalities. Human Molecular Genetics 2001; 10:2717-26.
62. Tang W, Sencer S, Hamilton SL Calmodulin modulation of proteins involved in excitation-contraction coupling. Frontiers in Bioscience 2002; 7:1583-9.
63. Tang ZZ, Yarotskyy V, Wei L., Sobczak K, Nakamori M, Eichinger K., et al Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of CaV 1.1 calcium channel. Human Molecular Genetics 2012; 21:1312-24.
64. Thornell LE, Lindstom M, Renault V., Klein A, Mouly V, Ansved T., et al Satellite cells dysfunction contributes to the progressive muscle atrophy in myotonic dystrophy type 1. Neuropathology and Applied Neurobiology 2009; 35:603-13.
65. Timchenko LT. Myotonic dystrophy: the role of RNACUG repeats. American Journal of Human Genetics 1999; 64:360-4.
66. Timchenko LT, Miller JW, Timchenko N.A., DeVore DR, Datar KV, Lin L, et al Identification of a (CUG)n triplet repeat binding protein and its expression in myotonic dystrophy. Nucleic Acids Research 1996a; 24:4407-14.
67. Timchenko LT, Salisbury E, Wang G-L, Nguyen H, Albrecht J.H., Hershey JWB, et al Age specific CUGBP1-eIF2 complex increases translation of CCAAT/enhancer-binding protein beta in old liver. Journal of Biological Chemistry 2006; 281:32806-19.
68. Timchenko LT, Timchenko NA, Caskey C.T., Roberts R. Novel proteins with binding specificity to DNA CTG and RNA CUG repeats: implications for myotonic dystrophy. Human Molecular Genetics 1996b; 5:115-21.
69. Timchenko NA, Cai Z-J, Welm AL, Reddy S, Ashizawa T., Timchenko LT RNA CUG repeats sequester and alter protein levels and activity of CUGBP1. Journal of Biological Chemistry 2001; 276:7820-6.
70. Timchenko NA, Patel R, Iakova P., Cai Z-J, Quan L, Timchenko LT Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis. Journal of Biological Chemistry 2004; 279:13129-39.
71. Timchenko NA, Wang G-L, Timchenko LT RNA CUG-binding protein 1 increases translation of 20-kDa isoform of CCAAT/enhancer-binding protein beta by interacting with the alpha and beta subunits of eukaryotic initiation translation factor 2. Journal of Biological Chemistry 2005; 280:20549-57.
72. Tintignac LA, Lagirand J, Batonnet S., Sirri V, Leibovitch MP, Leibovitch SA Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. Journal of Biological Chemistry 2005; 280:2847-56.
73. Vignaud A, Ferry A, Huguet A., Baraibar M, Trollet C, Hyzewicz J., et al Progressive skeletal muscle weakness in transgenic mice expressing CTG expansions is associated with the activation of the ubiquitin-proteasome pathway. Neuromuscular Disorders 2010; 20(5):319-25.
74. Vihola A, Bassez G, Meola G., Zhang S, Haapasalo H, Paetau A., et al Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology 2003; 60:1854-7.
75. Vlasova IA, Tahoe NM, Fan D, Larsson O., Rattenbacher B, Sternjohn JR, et al. Conserved GU-rich elements mediate mRNA decay by binding to CUG-binding protein 1. Molecular Cell 2008; 29:263-70.
76. Wang ET, Cody NA, Jog S, Biancolella M., Wang TT, Treacy DJ, et al Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell 2012; 150:710-24.
77. Wang GS, Kuyumcu-Martinez MN, Sarma S., Mathur N, Wehrens XHT, Cooper TA PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. Journal of Clinical Investigation 2009; 119: 3797-806.
78. Ward AJ, Rimer M, Killian J.M., Dowling JJ, Cooper TA CUGBPl overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Human Molecular Genetics 2010; 19:3614-22.
79. Wheeler TM, Leger AJ, Pandey S.K., MacLeod AR, Nakamori M, Cheng SH, et al Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 2012; 488:111-5.
80. Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, Dirksen RT, et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009; 325:336-9.
81. Whitman SA, Cover C, Yu L., Nelson DL, Zarnescu DC, Gregorio CC Desmoplakin and talin 2 are novel mRNA targets of fragile X-related protein-1 in cardiac muscle. Circulation Research 2011; 109:262-71.
82. Zhang L, Lee JE, Wilusz J, Wilusz CJ. The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells: implications for myotonic dystrophy. Journal of Biological Chemistry 2008; 283:22457-63.
83. Zu T, Gibbens B, Doty N.S., Gomes-Pereira M, Huguet A, Stone M.D., Margolis J., et al Not-ATG-initiated translation directed by microsatellite. Proceedings of the National Academy of Sciences of the United States of America 2011; 108:260-5.